title: Effectiveness of adding vildagliptin to the treatment of diabetic patients nonresponsive to the combination of metformin and a sulphonylurea.
abstract: OBJECTIVE
  To evaluate the effectiveness of adding vildagliptin to the treatment of patients with inadequately controlled type 2 diabetes mellitus (T2DM) treated with a combination of metformin and a sulphonylurea.
  
  
  METHODS
  37 T2DM patients with HbA1c ranging from 7.7% to 12.4% (mean of 9.30 ± 1.38), despite the use of metformin in combination with a sulphonylurea, were additionally treated with vildagliptin (100 mg/day) for at least 6 months.
  
  
  RESULTS
  During triple oral therapy (TOT) HbA1c levels < 7% were achieved in 11 patients (29.7%), whereas levels of fasting plasma glucose (FPG) < 120 mg/dL were observed in 12 patients (32.4%). Both findings were observed in 10 patients (27.0%). Compared to nonresponsive subjects, lower mean baseline HbA1c and FPG levels were seen in responsive patients, but the difference was only statistically significant for fasting plasma glucose (FPG). Moreover, there was considerable overlap between the two groups.
  
  
  CONCLUSIONS
  Our preliminary results suggest that TOT with metformin, a sulphonylurea and vildagliptin may be useful for some T2DM patients nonresponsive to combination therapy with metformin and sulphonylurea.
authors.affiliation: Center for Diabetes and Endocrinology of Pernambuco, Recife, PE, Brazil. lvilarf@mail.com
authors.forename: Lucio
authors.initials: L
authors.lastname: Vilar
authors.forename: Amaro
authors.initials: A
authors.lastname: Gusmão
authors.forename: José Luciano
authors.initials: JL
authors.lastname: Albuquerque
authors.forename: Lisete
authors.initials: L
authors.lastname: Pontes
authors.forename: Larissa
authors.initials: L
authors.lastname: Montenegro
authors.forename: Soraya
authors.initials: S
authors.lastname: Pontes
authors.forename: George Robson
authors.initials: GR
authors.lastname: Ibiapina
authors.forename: Rodrigo Andrade
authors.initials: RA
authors.lastname: Cunha
authors.forename: Gercivan dos Santos
authors.initials: Gdos S
authors.lastname: Alves
authors.forename: Viviane
authors.initials: V
authors.lastname: Canadas
authors.forename: Vera Maria Santos G
authors.initials: VM
authors.lastname: Ferreira
authors.forename: Lucia Helena Coelho
authors.initials: LH
authors.lastname: Nóbrega
authors.forename: Josivan Gomes de
authors.initials: JG
authors.lastname: Lima
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000284:Administration, Oral; D000328:Adult; D000704:Analysis of Variance; D001786:Blood Glucose / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004359:Drug Therapy, Combination / Q000379:methods; D005215:Fasting / Q000097:blood; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D008297:Male; D008687:Metformin / Q000008:administration & dosage*; D008875:Middle Aged; D009570:Nitriles / Q000627:therapeutic use*; D011759:Pyrrolidines / Q000627:therapeutic use*; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D013997:Time Factors; D017211:Treatment Failure; D016896:Treatment Outcome; D000077597:Vildagliptin
chemical_list: D000218:Adamantane; D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D008687:Metformin; D009570:Nitriles; D011759:Pyrrolidines; D013453:Sulfonylurea Compounds; D000077597:Vildagliptin